Anti-cancer activity of carvedilol and its isomers

A method for inhibiting epidermal growth factor dependent proliferation in cancer cells comprising administering an effective amount of carvedilol, an S(−) or R(+) isomer of carvedilol or a mixture thereof to a patient in need thereof.

A method for inhibiting epidermal growth factor dependent proliferation in cancer cells comprising incubating with or adding to the cancer cells an effective amount of carvedilol, an S(−) or R(+) isomer of carvedilol or a mixture thereof in vitro, or administering said carvedilol, an (S)(−) or R(+) isomer of carvedilol, or a mixture thereof to a patient in need thereof.

A method for inhibiting platelet derived growth factor dependent proliferation in cancer cells comprising administering to a patient in need thereof an effective amount of carvedilol, an S(−) or R(+) isomer of carvedilol or a mixture thereof.

A method of inhibiting epidermal growth factor dependent proliferation in cancer cells comprising administering an effective amount of carvedilol, an S(−) or R(+) isomer of carvedilol or a mixture thereof to cancer cells in vitro.

A method of treating cancer by inhibiting epidermal growth factor dependent proliferation in cancer cells comprising administering an effective amount of carvedilol, an S(−) or R(+) isomer of carvedilol or a mixture thereof to a patient in need thereof.

A method of inhibiting platelet derived growth factor dependent proliferation in cancer cells comprising administering an effective amount of carvedilol, an S(−) or R(+) isomer of carvedilol or a mixture thereof to cancer cells in vitro.

A method of treating cancer by inhibiting platelet derived growth factor dependent proliferation in cancer cells comprising administering an effective amount of carvedilol, an S(−) or R(+) isomer of carvedilol or a mixture thereof to a patient in need thereof.

A method of inhibiting intracellular Protein Kinase C activity in cancer cells comprising administering an effective amount of carvedilol, an S(−) or R(+) isomer of carvedilol or a mixture thereof to cancer cells in vitro.

A method of treating cancer by intracellular inhibition of Protein Kinase C activity in cancer cells comprising administering an effective amount of carvedilol, an S(−) or R(+) isomer of carvedilol or a mixture thereof administered to a patient in need thereof.

A method of blocking intracellular PI3 Kinase in cancer cells comprising administering an effective amount of carvedilol, an S(−) or R(+) isomer of carvedilol or a mixture thereof to cancer cells in vitro.

A method of treating cancer by intracellular blocking of PI3 Kinase in cancer cells comprising administering an effective amount of carvedilol, an S(−) or R(+) isomer of carvedilol or a mixture thereof a patient in need thereof.

A method of inhibiting cyclooxygenase 2 enzyme in cancer cells comprising administering an effective amount of carvedilol, an S(−) or R(+) isomer of carvedilol or a mixture thereof to cancer cells in vitro.

A method of treating cancer by inhibiting cyclooxygenase 2 enzyme in cancer cells comprising administering an effective amount of carvedilol, an S(−) or R(+) isomer of carvedilol or a mixture thereof to a patient in need thereof.